REFERENCES
Alam, S., Kamal, T. B., Sarker, M. M. R., Zhou, J. R., Rahman, S. M. A.,
& Mohamed, I. N. (2021). Therapeutic Effectiveness and Safety of
Repurposing Drugs for the Treatment of COVID-19: Position Standing in
2021. Front Pharmacol, 12 , 659577. doi:10.3389/fphar.2021.659577
Asano, T., Tanaka, K. I., Tada, A., Shimamura, H., Tanaka, R., Maruoka,
H., … Takenaga, M. (2017). Ameliorative effect of chlorpromazine
hydrochloride on visceral hypersensitivity in rats: possible involvement
of 5-HT2A receptor. Br J Pharmacol, 174 (19), 3370-3381.
doi:10.1111/bph.13960
Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque,
S. (2021). Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From
Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.Front Med (Lausanne), 8 , 615978. doi:10.3389/fmed.2021.615978
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat,
M. L., & Gabbiani, G. (2007). The myofibroblast: one function, multiple
origins. Am J Pathol, 170 (6), 1807-1816. doi:
10.2353/ajpath.2007.070112
Hironaka, T., Ueno, T., Mae, K., Yoshimura, C., Morinaga, T., Horii, Y.,
… Nakaya, M. (2020). Drebrin is induced during myofibroblast
differentiation and enhances the production of fibrosis-related genes.Biochem Biophys Res Commun, 529 (2), 224-230.
doi:10.1016/j.bbrc.2020.05.110
Huang, C., Xiao, X., Yang, Y., Mishra, A., Liang, Y., Zeng, X., …
Liu, L. (2017). MicroRNA-101 attenuates pulmonary fibrosis by inhibiting
fibroblast proliferation and activation. J Biol Chem, 292 (40),
16420-16439. doi:10.1074/jbc.M117.805747
Im, J., Lawrence, J., Seelig, D., & Nho, R. S. (2018). FoxM1-dependent
RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis
fibroblasts from radiation-induced cell death. Cell Death Dis,
9 (6), 584. doi:10.1038/s41419-018-0652-4
Iwase, S., Mano, T., Saito, M., & Ishida, G. (1992). Effect of a
centrally-acting muscle relaxant, eperisone hydrochloride, on muscle
sympathetic nerve activity in humans. Funct Neurol, 7 (6),
459-470.
Kim, D. S., Collard, H. R., & King, T. E., Jr. (2006). Classification
and natural history of the idiopathic interstitial pneumonias.Proc Am Thorac Soc, 3 (4), 285-292. doi: 10.1513/pats.200601-005TK
Kinnula, V. L., & Myllarniemi, M. (2008). Oxidant-antioxidant imbalance
as a potential contributor to the progression of human pulmonary
fibrosis. Antioxid Redox Signal, 10 (4), 727-738. doi:
10.1089/ars.2007.1942
Kisseleva, T., & Brenner, D. A. (2008). Fibrogenesis of parenchymal
organs. Proc Am Thorac Soc, 5 (3), 338-342. doi:
10.1513/pats.200711-168DR
Luppi, F., Cerri, S., Beghe, B., Fabbri, L. M., & Richeldi, L. (2004).
Corticosteroid and immunomodulatory agents in idiopathic pulmonary
fibrosis. Respir Med, 98 (11), 1035-1044. doi:
10.1016/j.rmed.2004.07.019
Maher, T. M., Evans, I. C., Bottoms, S. E., Mercer, P. F., Thorley, A.
J., Nicholson, A. G., … McAnulty, R. J. (2010). Diminished
prostaglandin E2 contributes to the apoptosis paradox in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med, 182 (1), 73-82.
doi:10.1164/rccm.200905-0674OC
Mizushima, T. (2011). Drug discovery and development focusing on
existing medicines: drug re-profiling strategy. J Biochem,
149 (5), 499-505. doi:mvr032 [pii]
10.1093/jb/mvr032
Nair, A. B., & Jacob, S. (2016). A simple practice guide for dose
conversion between animals and human. J Basic Clin Pharm, 7 (2),
27-31. doi:10.4103/0976-0105.177703
Nakano, Y., Shimoda, M., Okudomi, S., Kawaraya, S., Kawahara, M., &
Tanaka, K. I. (2020). Seleno-l-methionine suppresses copper-enhanced
zinc-induced neuronal cell death via induction of glutathione
peroxidase. Metallomics, 12 (11), 1693-1701.
doi:10.1039/d0mt00136h
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M.
K., Kardatzke, D., … Group, C. S. (2011). Pirfenidone in patients
with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet, 377 (9779), 1760-1769. doi:10.1016/S0140-6736(11)60405-4
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S.,
Wells, A., … Pirmohamed, M. (2019). Drug repurposing: progress,
challenges and recommendations. Nat Rev Drug Discov, 18 (1),
41-58. doi:10.1038/nrd.2018.168
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J.,
… Latin American Thoracic, A. (2015). An Official
ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic
Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Am J Respir Crit Care Med, 192 (2), e3-19.
doi:10.1164/rccm.201506-1063ST
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K.,
Costabel, U., … Investigators, I. T. (2014). Efficacy and safety
of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med,
370 (22), 2071-2082. doi:10.1056/NEJMoa1402584
Scotton, C. J., & Chambers, R. C. (2007). Molecular targets in
pulmonary fibrosis: the myofibroblast in focus. Chest, 132 (4),
1311-1321. doi:10.1378/chest.06-2568
Sheppard, D. (2006). Transforming growth factor beta: a central
modulator of pulmonary and airway inflammation and fibrosis. Proc
Am Thorac Soc, 3 (5), 413-417. doi: 10.1513/pats.200601-008AW.
Song, M. J., Moon, S. W., Choi, J. S., Lee, S. H., Lee, S. H., Chung, K.
S., … Kim, S. Y. (2020). Efficacy of low dose pirfenidone in
idiopathic pulmonary fibrosis: real world experience from a tertiary
university hospital. Sci Rep, 10 (1), 21218.
doi:10.1038/s41598-020-77837-x
Sugizaki, T., Tanaka, K. I., Asano, T., Kobayashi, D., Hino, Y.,
Takafuji, A., … Mizushima, T. (2019). Idebenone has preventative
and therapeutic effects on pulmonary fibrosis via preferential
suppression of fibroblast activity. Cell Death Discov, 5 , 146.
doi:10.1038/s41420-019-0226-y
Tanaka, K., Azuma, A., Miyazaki, Y., Sato, K., & Mizushima, T. (2012).
Effects of lecithinized superoxide dismutase and/or pirfenidone against
bleomycin-induced pulmonary fibrosis. Chest, 142 (4), 1011-1019.
doi: 10.1378/chest.11-2879
Tanaka, K., Ishihara, T., Sugizaki, T., Kobayashi, D., Yamashita, Y.,
Tahara, K., … Mizushima, T. (2013). Mepenzolate bromide displays
beneficial effects in a mouse model of chronic obstructive pulmonary
disease. Nat Commun, 4 , 2686. doi:10.1038/ncomms3686
Tanaka, K. I., Niino, T., Ishihara, T., Takafuji, A., Takayama, T.,
Kanda, Y., … Mizushima, T. (2017). Protective and therapeutic
effect of felodipine against bleomycin-induced pulmonary fibrosis in
mice. Sci Rep, 7 (1), 3439. doi:10.1038/s41598-017-03676-y
Tanaka, K. I., Shimoda, M., Kasai, M., Ikeda, M., Ishima, Y., &
Kawahara, M. (2019). Involvement of SAPK/JNK Signaling Pathway in Copper
Enhanced Zinc-Induced Neuronal Cell Death. Toxicol Sci, 169 (1),
293-302. doi:10.1093/toxsci/kfz043
Tekes, K. (2014). Basic aspects of the pharmacodynamics of tolperisone,
a widely applicable centrally acting muscle relaxant. Open Med
Chem J, 8 , 17-22. doi:10.2174/1874104501408010017
Thannickal, V. J., & Horowitz, J. C. (2006). Evolving concepts of
apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc,
3 (4), 350-356. doi:10.1513/pats.200601-001TK
Tsoyi, K., Chu, S. G., Patino-Jaramillo, N. G., Wilder, J., Villalba,
J., Doyle-Eisele, M., … Rosas, I. O. (2017). Syndecan-2
Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast
Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. Am J
Respir Cell Mol Biol doi:10.1165/rcmb.2017-0088OC
Walter, N., Collard, H. R., & King, T. E., Jr. (2006). Current
perspectives on the treatment of idiopathic pulmonary fibrosis.Proc Am Thorac Soc, 3 (4), 330-338. doi: 10.1513/pats.200602-016TK
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019). Organ and tissue
fibrosis: Molecular signals, cellular mechanisms and translational
implications. Mol Aspects Med, 65 , 2-15.
doi:10.1016/j.mam.2018.06.003
Woessner, J. F., Jr. (1961). The determination of hydroxyproline in
tissue and protein samples containing small proportions of this imino
acid. Arch Biochem Biophys, 93 , 440-447. doi:
10.1016/0003-9861(61)90291-0
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B.
(2014). Antifibrotic and anti-inflammatory activity of the tyrosine
kinase inhibitor nintedanib in experimental models of lung fibrosis.Journal of Pharmacology and Experimental Therapeutics, 349 (2),
209-220. doi:10.1124/jpet.113.208223
Yuan, Q., Tan, R. J., & Liu, Y. (2019). Myofibroblast in Kidney
Fibrosis: Origin, Activation, and Regulation. Adv Exp Med Biol,
1165 , 253-283. doi:10.1007/978-981-13-8871-2_12